NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
0.809
+0.058 (7.78%)
Apr 28, 2026, 4:00 PM EDT - Market closed
NeuroSense Therapeutics Employees
NeuroSense Therapeutics had 17 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
17
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$654,412
Market Cap
28.59M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 17 | 0 | - |
| Dec 31, 2024 | 17 | -1 | -5.56% |
| Dec 31, 2023 | 18 | 4 | 28.57% |
| Dec 31, 2022 | 14 | 3 | 27.27% |
| Dec 31, 2021 | 11 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Longeveron | 38 |
| Jasper Therapeutics | 22 |
| Lisata Therapeutics | 21 |
| ABVC BioPharma | 19 |
| Lantern Pharma | 16 |
| Barinthus Biotherapeutics | 14 |
| Apollomics | 13 |
| AEON Biopharma | 8 |
NRSN News
- 14 hours ago - NeuroSense Announces Pricing of Insider-Led PIPE Financing - PRNewsWire
- 22 days ago - NeuroSense Granted Brazilian Patent Covering PrimeC Composition - PRNewsWire
- 25 days ago - NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements - PRNewsWire
- 4 weeks ago - NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update - PRNewsWire
- 5 weeks ago - NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout - PRNewsWire
- 5 weeks ago - PrimeC New Data to Be Presented at AD/PD™ 2026 Conference - PRNewsWire
- 6 weeks ago - JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity - PRNewsWire
- 7 weeks ago - PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference - PRNewsWire